MedTrace Logo

4-Week, Multiple-dose, Dose-escalating Study In Patients With Type 2 Diabetes

NCT03538743 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 98

Last updated 2020-07-01

Study results available
· View outcomes & findings →

Summary

This is a dose-escalating study in patients with Type 2 diabetes on metformin. Participants will receive an investigational product or placebo for 28 days.

Conditions

Interventions

DRUG

Placebo

Tablet, 0 mg, twice daily, 28 days

DRUG

PF-06882961

Tablet, 15 mg twice daily, 28 days

DRUG

PF-06882961

Tablet, 50 mg twice daily, 28 days

DRUG

PF-06882961

Tablet, 150 mg twice daily, 28 days

DRUG

PF-06882961

Tablet, 300 mg twice daily, 28 days

DRUG

PF-06882961

Tablet, dose TBD, twice daily, Cohort 5, 28 days

DRUG

PF-06882961

Tablet, dose TBD, twice daily, Cohort 6, 28 days

DRUG

PF-06882961

Tablet, dose TBD, twice daily, Cohort 7, 28 days

DRUG

PF-06882961

Tablet, dose TBD, twice daily, Cohort 8, 28 days

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-25
Primary Completion
2019-05-23
Completion
2019-06-10
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03538743 on ClinicalTrials.gov